Cardiovascular disease in the antiphospholipid syndrome
Related Experiment Video
Updated: Apr 23, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Jenny Amaya-Amaya1, Adriana Rojas-Villarraga1, Juan-Manuel Anaya2
1Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia; and Mederi, Hospital Universitario Mayor, Bogotá, Colombia.
Insights
Cardiovascular disease (CVD) in antiphospholipid syndrome (APS) is influenced by various factors beyond traditional risks. Novel risk factors contribute significantly to premature CVD and vascular damage in APS patients.
Area of Science:
- Rheumatology
- Cardiology
- Immunology
Background:
- Antiphospholipid syndrome (APS) is associated with a high prevalence of cardiovascular disease (CVD).
- The exact prevalence and causes of CVD in APS are not fully understood and vary based on detection methods.
- Atherosclerosis, a key driver of CVD, involves endothelial damage and is considered an autoimmune-inflammatory process.
Purpose of the Study:
- To review the significance and outcomes of cardiovascular disease (CVD) in patients with antiphospholipid syndrome (APS).
- To explore the contribution of novel risk factors to premature CVD in APS.
- To understand the mechanisms of accelerated vascular damage in APS.
Main Methods:
- Literature review of studies on CVD in APS.
- Analysis of diagnostic criteria and detection tools for CVD in APS cohorts.
- Examination of traditional and novel cardiovascular risk factors in APS patients.
Main Results:
- CVD prevalence in APS varies significantly across studies.
- Traditional risk factors do not fully explain the excess cardiovascular events in APS.
- Novel risk factors play a crucial role in the development of premature CVD and vascular damage in APS.
Conclusions:
- Cardiovascular disease is a major concern in antiphospholipid syndrome.
- Understanding novel risk factors is essential for managing CVD in APS.
- Further research is needed to elucidate the complex relationship between APS and cardiovascular outcomes.
Abstract:
The prevalence of cardiovascular disease (CVD) in antiphospholipid syndrome (APS) varies from one series to another depending on the definition of CVD and tools used for its detection. Atherosclerosis, the usual cause of CVD, starts when the endothelium becomes damaged and is considered to be an autoimmune-inflammatory disease. The excessive cardiovascular events observed in patients with APS are not fully explained by traditional risk factors. Therefore, several novel risk factors contribute to the development of premature CVD and accelerated vascular damage in those patients. Herein, the significance and outcomes of CVD in APS are reviewed.
Related Concept Videos
Peripheral Artery Disease I: Introduction
Peripheral Artery Disease III: Interprofessional Care
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Rheumatic Heart Disease I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
